A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

Exclusion Criteria

• •1\. Concomitant disease and medical history:
• •1. There were other malignant tumors in 3 years before the first medication.
• •2. Has multiple factors affecting oral medication;
• •3. Unalleviated toxicity ≥ grade 1 due to any previous therapy;
• •4. Major surgical treatment, open biopsy and obvious traumatic injury were performed within 28 days before the study; e．Arteriovenous thrombotic events occurred within 6 months before the first medication, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism; f．Have a history of psychotropic drug abuse and can not quit or have mental disorders; g．Subjects with any severe and / or uncontrolled disease included: Cirrhosis, active hepatitis, history of immunodeficiency;
• •Tumor-related symptoms and treatment:
• •1. Has central nervous system metastases (CNS) and/or cancerous meningitis or leptomeningeal carcinomatosis;
• •2. have received radiotherapy, other antineoplastic therapy within 2 weeks prior to the first dose;
• •3. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
• •Known hypersensitivity to TQB3909, LHRH agonists (e.g., goserelin), or any excipients.
• •Subjects who have received the vaccine within 28 days prior to the first dose, or are planning to receive the vaccine during the study period.
• •Has Participated in other clinical trials within 4 weeks before first dose.
• •According to the judgement of the investigators, there are other factors that may lead to the termination of the study.